Skip to main content
OpenTrials
Completed

NCT Number: NCT06654687

Transthoracic Echocardiographic Monitoring of Cardiac Output Effects of Colloid Preload and Crystalloid Coload During Cesarean Delivery Under Spinal Anesthesia

Transthoracic echocardiography (TTE) has been introduced in anesthesia and intensive care practice to assess the volume status and predict fluid responsiveness, with a few studies performed on pregnant women (5).

In this study, we aim to evaluate the effect of intravenous administration of albumin as a colloid preload on the maternal stroke volume (SV) and cardiac output (CO) versus crystalloid coload. We used TTE to measure the changes in SV, and CO at baseline and at subsequent time points after spinal anesthesia.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Mansoura University

Al Mansurah, Egypt

About this study

This prospective randomized controlled, double-blind study will be conducted at the obstetrics and gynecology operation room, at Qassim University Medical City.

Written informed consent will be obtained from eligible subjects on the day of the surgery. The study subjects will be randomized using the R software, version 3.5.2 (R Core Team, 2018; R Foundation for Statistical Computing, Vienna, Austria). Subjects will randomly be assigned to 2 equal groups (combined and crystalloid coload) using the permuted block randomization method with randomly selected block sizes of 4 and 6. The group allocation codes will be hidden in sequentially numbered, opaque, sealed envelopes that will be opened only after assessing the eligibility and obtaining the consent from the subjects. The study subjects and the outcome assessors will be blinded to the study group.

Spinal anesthesia will be conducted will be assessed respectively by an anesthesiologist not involved in the study.

All transthoracic cardiography images will be obtained by the second investigator who have the experience of accomplishing > 500 cases before starting the study using the technique and guidelines reported in American Society of Echocardiography . During obtaining the images intraoperatively, the investigator will be separated from the surgical field by a sterile drape, and the ultrasound probe will be covered with a sterile cover.

The study subjects will enter the operating room, lying supine on the operating table with slight left lateral position by tilting the operating table to the left. Standard monitors will be attached to all patients (noninvasive blood pressure, pulse oximeter, and electrocardiography). Basal systolic blood pressure and heart rate will be recorded after a period of rest, the average of 3 readings, 2 minutes apart will be recorded. Basal transthoracic cardiography images will be obtained.

Two 18-gauge intravenous cannula will be inserted in two large veins of the right forearm, one for IV fluids, and the other for phenylephrine infusion. In the combination group, patients will receive 250 mL of human albumin 5% (Human Albumin 50 gm/L, BAXTER, Austria) immediately before induction of spinal anesthesia (SA), over 10 minutes using an infusion pump (Fresenius Kabi Agilia Volumat MC Infusion Pump, Germany), and 750 mL of Ringer's lactate solution, to be started during the intrathecal injection of the local anesthetic, and infused over 15 minutes. In the crystalloid coload group, patients will receive 1000 mL of Ringer's lactate solution, to be started during the intrathecal injection of the local anesthetic, and infused over 15 minutes. In both groups, phenylephrine infusion will be given prophylactically, and will be started during the intrathecal injection of the local anesthetic at a dose ranging from 25-50 mcg/minute to maintain the SBP within 20 % of the basal readings. After administering the study solutions, Ringer's lactate will be attached to the IV cannula and will be administered at a rate of 1 mL/min; no other fluids will be administered until clamping of the umbilical cord (end of the study period).

In the sitting position, spinal anesthesia will be conducted by intrathecal injection of hyperbaric bupivacaine 12.5 mg 0.5% and fentanyl 15 microgram, using 27-gauge pencil point spinal needle at L3-L4 intervertebral space.

Surgery will be started after reaching at least an upper sensory level of T4; below this level, spinal anesthesia will be considered failed and patients will be excluded from the study.

SV and CO will be measured at 5 time points (basal readings, 1 minute after SA, 5 minutes after SA, immediately after delivery of the baby and clamping the cord, and 1 hour after the end of the study). SBP and HR will be recorded ever minute till the delivery of the baby, then every 3 minutes till the end of the surgery.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • American Society of Anesthesiologists physical status II parturients with full term singleton pregnancies scheduled for elective cesarean delivery under spinal anesthesia.

Exclusion criteria

  • Height <150 cm, weight <55 kg, and body mass index ≥40 kg/m2.
  • Women presenting in labor or having any contraindication to spinal anesthesia (patient refusal, increased intracranial pressure, coagulation disorders, or local skin infection).
  • Chronic or pregnancy-induced hypertension; baseline systolic blood pressure >140 mm Hg.
  • Hemoglobin <10 g/dL.
  • Diabetes mellitus.
  • Cardiovascular, cerebrovascular, or renal disease.
  • Polyhydramnios or fetal abnormalities.

Treatment and study plan

Transthoracic echocardiography

Device

Transthoracic Echocardiography will be used to measure the changes in stroke volume and cardiac output.

Ringer lactate 1000 ml

Drug

Patients will receive 1000 mL of Ringer's lactate solution over 15 minutes.

ALBUMIN

Drug

Patients will receive 250 mL of human albumin 5% over 10 minutes

Ringer lactate 750 ml

Drug

Patients will receive 750 mL of Ringer's lactate solution over 15 minutes.

Primary outcomes

  1. Changes in Cardiac Output

    Time frame: Immediately after delivery of baby

    The changes in Cardiac Output are measured relative to baseline immediately after delivery

Secondary outcomes

  1. Changes in stroke volume

    Time frame: Immediately after delivery of baby

    The changes in stroke volume are measured compared to the baseline immediately after delivery

  2. Total phenylephrine dose (mg)

    Time frame: Until delivery of baby

  3. Total ephedrine dose (mg)

    Time frame: Until delivery of the baby

  4. Total glycopyrrolate dose (mg)

    Time frame: Until delivery of the baby

  5. Incidence of hypotension

    Time frame: Until end of surgery

    Decrease in SBP > 20% of the basal reading

  6. Incidence of bradycardia

    Time frame: Until end of surgery

    Heart rate < 50 beats/minute

  7. Incidence of nausea and/or vomiting

    Time frame: Until end of surgery

  8. Measurement of APGAR score

    Time frame: 1 minute and 5 minutes after delivery of the baby

    APGAR score includes appearance, pulse, grimace, activity and respiration

  9. Measurement of Urine output (ml)

    Time frame: 1 hour after delivery of the baby

Sponsors and collaborators

Lead sponsor

Sameh Fathy

Other

Registry information

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Oct 23, 2024
Registry last updated
May 21, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.